New CB1-SSi

About Aelis Farma

Aelis Farma is a clinical-stage biotech pioneering a new class of drugs called Signaling Specific inhibitors (CB1-SSi) that selectively block pathological signaling of the cannabinoid CB1 receptor without disrupting its normal function. Its lead asset, AEF0117, is in Phase 2b for cannabis use disorder, while its second candidate, AEF0217, is entering Phase 1/2 for cognitive deficits in Down syndrome. The company leverages a proprietary platform to generate new molecular entities and is supported by prestigious non-dilutive grants from the NIH and EU, positioning it at the frontier of neuropsychiatric pharmacology.

Therapeutic Areas